US Patent

US11782041 — Abaloparatide formulations and methods of testing, storing, modifying, and using same

Method of Use · Assigned to Radius Health Inc · Expires 2038-04-30 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of analyzing, storing, and using abaloparatide, specifically in relation to its newly discovered isomers.

USPTO Abstract

Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.

Drugs covered by this patent

Tymlos (ABALOPARATIDE) · Radius

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2009`	—	Tymlos

Patent Metadata

Patent number: US11782041
Jurisdiction: US
Classification: Method of Use
Expires: 2038-04-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Radius Health Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.